Evidence-Based Vision Therapy Protocol for Convergence Insufficiency

2 de julio de 2026
A Brock string with colored beads and prism flipper lenses arranged on a clean white surface under soft clinical lighting, representing vision therapy tools used in convergence insufficiency treatment.
Publicado en  Actualizado en  

Why Protocol Design Determines CI Outcomes

Approximately 27% of convergence insufficiency patients do not improve even with validated therapy, according to data from ClinicalTrials.gov. That statistic should give every clinician pause. Protocol design, tool selection, and progression sequencing are not afterthoughts; they are the critical variables separating responders from non-responders.

Convergence insufficiency (CI) is a non-strabismic binocular vision disorder characterized by an inability to maintain adequate convergence for near tasks. The two primary diagnostic markers are a receded near point of convergence (NPC) and reduced positive fusional vergence (PFV). A pooled global prevalence of 7.98% across 35 studies has been reported by the Open Ophthalmology Journal, with roughly 5% prevalence in school-age children and approximately 1 in 6 adults affected, per StatPearls.

The landmark Convergence Insufficiency Treatment Trial (CITT) provides Level I evidence for protocol decisions. This randomized clinical trial enrolled 221 children aged 9 to 17 across four treatment arms over a 12-week protocol. Office-based vergence/accommodative therapy (OBVAT) emerged as the gold standard, with a home compliance rate of 91.4%, compared to just 67.3% for home-based computer vergence therapy. That gap confirms what experienced therapists already know: the right tools and a structured in-office protocol drive adherence. This article delivers a phased, tool-specific, evidence-grounded protocol using prisms, flippers, and Brock strings.

Diagnosing and Baselining CI Before Therapy Begins

Before initiating any therapy sequence, two clinical markers must be measured and documented. An NPC receded beyond 6 cm is considered abnormal. PFV below 15 prism diopters (Δ) fails Sheard's criterion, the clinical decision framework that determines whether base-in prism prescription is warranted and at what magnitude. Sheard's criterion states that fusional vergence reserves should be at least twice the phoria; when they fall short, the deficit quantifies both symptom risk and potential prism magnitude. This is a practical gap most published protocol summaries overlook.

The Convergence Insufficiency Symptom Survey (CISS) serves as the quantitative baseline tool. A successful outcome is defined as a CISS score below 16, combined with NPC under 6 cm and PFV exceeding 15Δ passing Sheard's criterion. The CISS should be administered at intake, again at 6 weeks, and at 12 weeks. Using it only at diagnosis forfeits its value as a longitudinal tracking instrument.

Clinicians should also be alert to the CI and ADHD differential diagnosis challenge. Research published in PMC (2024) suggests that poor binocular test performance in children with ADHD may reflect inattention rather than a primary binocular vision dysfunction. Screen carefully before attributing test failures to CI and committing to a therapy protocol.

Finally, distinguish typical CI (TYP-CI) from concussion-related CI (CONC-CI). The 2025 CONCUSS randomized clinical trial established CONC-CI as a clinically distinct subtype requiring modified protocol considerations, including adjusted vergence demand and extended phase durations. This is addressed in detail below.

The Three Core Tools: Clinical Rationale and Setup Parameters

Before sequencing therapy phases, clinicians need clarity on each tool's mechanism, evidence base, and exact starting parameters. Here is the tool-by-tool foundation.

Base-In Prisms

Base-in prisms prescribed at near per Sheard's criterion provide symptomatic relief by reducing the convergence demand on the patient's system. However, prisms are palliative, not curative. They do not improve the underlying convergence ability. A 2024 randomized controlled trial (NCT05311917) directly compared base-in prism prescription against home vision therapy exercises in presbyopic CI patients, measuring CISS, NPC, near phoria, and PFV at baseline, 1 month, and 2 months. This trial underscores the role of prisms as a management option when active therapy is not feasible, or as an adjunct during early protocol phases, but not as a standalone treatment when vergence rehabilitation is the goal.

Prism Flippers

Loose stick prisms in the range of 8 to 10Δ base-out/base-in represent the published starting parameters for home-based CI protocols. The mechanism is jump vergence demand: alternating between base-out and base-in orientations forces the vergence system to make rapid, discrete step responses. This trains both convergence and divergence in a controlled, repeatable format. The alternating BO/BI sequence builds the step vergence responses that underpin real-world near task performance, as described in a published protocol for adults with CI.

Accommodative Flippers

Standard clinical power is ±2.00D. During binocular accommodative rock, the patient flips between plus and minus lenses while maintaining single, clear, stable binocular vision. This trains accommodative facility in tandem with vergence. Co-existing accommodative dysfunction is common in CI patients, a finding reinforced by CITT-ART data. Addressing both systems simultaneously improves functional outcomes.

Brock String

Bead placement at 10, 30, and 45 inches from the nose creates step vergence demands at near, mid, and far positions. The Brock string's feedback mechanism is physiological diplopia: when the patient fixates on one bead, the string appears to form an "X" at that bead, with the other beads appearing doubled. This immediate visual feedback lets the patient and clinician confirm accurate vergence posture in real time. A 2025 systematic review found insufficient evidence that VR-based tools outperform the Brock string, reinforcing its continued clinical primacy as a vergence training instrument.

Building the Phased Protocol: Session-by-Session Progression

The sequencing gap in most published CI guidance is the failure to specify a progression model. Effective protocols move from monocular to binocular to dynamic vergence. Here is how to structure that progression across the CITT's validated 12-week framework.

Phase 1: Monocular Foundation (Weeks 1–4)

Begin with monocular accommodative facility using ±2.00D flippers. The goal is to establish accommodative flexibility in each eye independently before introducing binocular demand. Patients flip lenses monocularly, targeting clear focus within one to two seconds per flip.

Simultaneously, introduce the Brock string with the near bead at 10 inches. At this stage, the objective is vergence awareness and physiological diplopia recognition, not vergence range. Confirm the patient can identify the "X" pattern and maintain fixation on the near bead for 30 seconds without suppression.

Phase 2: Binocular Integration (Weeks 5–8)

Advance to binocular accommodative rock with ±2.00D flippers. The patient now flips lenses while maintaining fusion binocularly, a significantly higher demand than monocular work. Monitor for suppression or diplopia during flips.

Introduce prism flippers at 8Δ base-out/base-in alternating. Begin with slow, controlled flips and increase speed as the patient demonstrates consistent fusion recovery. Move the Brock string bead to the mid position at 30 inches, increasing the vergence range demand. The patient should shift fixation between the near and mid beads, confirming physiological diplopia at each position.

Phase 3: Dynamic Vergence and Home Reinforcement (Weeks 9–12)

Advance prism flipper demand toward 10Δ. Move the Brock string to the far bead at 45 inches and practice smooth transitions across all three bead positions. If available, introduce vectograms or computer-based vergence programs to add variable demand. This phase aligns with the CITT's OBVAT structure: 12 one-hour weekly office sessions with concurrent home reinforcement.

Home reinforcement protocol: Based on the published home-based CI protocol, patients perform 10 minutes of prism stick exercises and 10 minutes of Brock string work, twice daily (morning and evening), over 18 days. CITT data showed home compliance ranged from 67% to 91% depending on the treatment arm. Strategies to improve compliance include setting specific daily times, using a tracking log, and scheduling brief check-in calls at weeks 2 and 4.

Augmented therapy option: For older teenagers and young adults, research published in Ophthalmology (AAO Journal) found that over-minus lenses combined with base-out prisms produced superior outcomes compared to standard office therapy at a lower treatment dose. Consider this approach for patients in this age range who plateau during Phase 2 or 3.

Adapting the Protocol for Special Populations

Concussion-Related CI (CONC-CI)

The 2025 CONCUSS randomized clinical trial, published in the British Journal of Sports Medicine (reported by AOA News), enrolled 106 participants aged 11 to 25 with persistent post-concussive symptoms 4 to 24 weeks post-injury. Office-based vergence/accommodative therapy with movement (OBVAM) significantly outperformed watchful waiting. Watchful waiting alone yielded only approximately 10% remediation, making early intervention imperative.

The CONCUSS fMRI sub-study, published in Frontiers in Neuroscience (October 2025), provided neuroimaging validation: OBVAM increased functional brain activity in the vergence oculomotor network, including the frontal eye fields, supplemental eye fields, parietal eye fields, cerebellar vermis, and visual cortex. The result is measurable neural reorganization, not symptom management alone.

Protocol modifications for CONC-CI: Reduce initial vergence demand (start prism flippers at 6Δ rather than 8Δ). Incorporate movement-based therapy components consistent with the OBVAM model. Monitor for symptom exacerbation after each session. Extend phase durations by 2 to 4 weeks given the slower neural recovery trajectory in post-concussive patients.

Presbyopic CI

The 2024 RCT (NCT05311917) compared home vision therapy (Brock string, barrel card, eccentric circles, and jump vergence exercises performed 3 days per week for 20 minutes) against base-in prism prescription in presbyopic CI patients, with outcomes measured at 1 and 2 months. For this population, accommodative flipper power may need to be reduced below ±2.00D given diminished accommodative amplitude. Focus on vergence-specific tools (Brock string, prism flippers) while adjusting accommodative demand to avoid frustration and false failure.

Pediatric CI with ADHD Comorbidity

Before attributing binocular test failures to CI in a child with known or suspected ADHD, rule out inattention as a confounding factor. Repeat testing under conditions that minimize attentional demand: shorter test sequences, frequent breaks, and high-engagement tasks. If CI is confirmed, consider shorter session durations (30 minutes instead of 60) and incorporate gamified or variable-format activities to sustain attention throughout the therapy session. Compliance monitoring is especially important in this group.

Tracking Outcomes and Knowing When to Modify

The CITT success criteria serve as the clinical benchmark at every checkpoint: CISS below 16, NPC under 6 cm, and PFV exceeding 15Δ passing Sheard's criterion. These are go/no-go decision points at 6 weeks and 12 weeks.

Administer the CISS at intake, week 6, and week 12. Document NPC and PFV at every session to detect plateau or regression early. A graph of NPC values over time is one of the most useful clinical tools for identifying stalls before the patient reports worsening symptoms.

Protocol modification triggers: No measurable NPC improvement by week 6, a CISS score that plateaus across two consecutive measurements, or a patient reporting increased symptoms after advancing demand. Each of these warrants stepping back one phase and reassessing tool parameters before progressing again.

Address the 27% non-responder reality directly. If a patient fails to meet CITT success criteria at 12 weeks, consider referral for augmented office-based therapy, prism prescription per Sheard's criterion for symptom management, or evaluation for co-existing conditions (accommodative insufficiency, decompensating phorias, or undiagnosed neurological factors).

Treatment duration in clinical studies ranged from 6 to 18 weeks, with Level I studies using 12 or 16 weeks. Individualize duration based on objective response, not a fixed calendar. A patient showing steady NPC improvement at week 12 may benefit from 4 additional weeks rather than premature discharge.

A note on emerging technology: a 2025 review confirmed that digital and remote vision therapy tools show promise but lack consistent methodology validation. Traditional tools remain the evidence-backed standard.

Building a Protocol That Works, and Documenting It

The phased framework outlined here follows a clear arc: baseline with CISS, NPC, and PFV; Phase 1 monocular accommodative foundation; Phase 2 binocular integration with prism flippers and expanded Brock string range; Phase 3 dynamic vergence with advanced demand and home reinforcement; and outcome reassessment at 12 weeks using the same validated criteria.

The evidence hierarchy supporting this approach is robust. CITT OBVAT remains the gold standard for typical CI. The 2025 CONCUSS RCT extends the evidence base to concussion-related CI. The 2024 presbyopic RCT addresses a population that most protocol guides ignore entirely.

Documentation is not optional. Record tool parameters at every session: prism diopter values, flipper power, Brock string bead positions, session duration, home compliance rates (ask directly and log the response), and CISS scores at each checkpoint. This documentation supports clinical decision-making, insurance justification, and contributes to the broader evidence base when aggregated across practices.

Practitioners looking for clinical-grade prism flippers, Brock strings, accommodative flippers, and CISS scoring tools can find them through Good-Lite, a trusted ophthalmic supply partner with deep roots in evidence-based vision care since 1930. Our product line supports every phase of this protocol, from baseline assessment through dynamic vergence training.

The CONCUSS fMRI sub-study confirmed that structured vergence therapy reshapes the brain's oculomotor network. Frontal eye fields, parietal eye fields, cerebellar vermis, visual cortex: all showed increased functional activity after OBVAM. A well-designed protocol delivers neurological rehabilitation, and the tools to deliver it are the same ones clinicians have trusted for decades.

Sources

Publicado en  Actualizado en  

últimos artículos

Etiqueta del botón